Cuvrior (Trientine Tetrahydrochloride) Patent Expiration, LOE Window & CMS Spending
Cuvrior (Trientine Tetrahydrochloride) by Orphalan Sa: FDA Orange Book core substance LOE 2039-05-03, 0 AB generics, $3.3M 2024 CMS Part D & Medicaid spend, and $13,752 CA SB 17 specialty launch WAC.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Orphalan Sa |
| FDA Application & Pathway | N215760 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | 2039-05-03 |
| Last Listed Patent or Exclusivity Date | 2039-05-03 |
| Orange Book Patents (*PED Extensions) | 5 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $3.3M |
| 2024 Medicare Part D Spend | $1.6M |
| 2024 Medicaid Spend | $1.7M |
| Reported Wholesale Price Change (CA SB 17) | Specialty launch notice ($13,752 intro WAC) |